BIOXCEL THERAPEUTICS INC (BTAI) Stock Price, Forecast & Analysis
USA - NASDAQ:BTAI - US09075P2048 - Common Stock
BTAI Key Statistics, Chart & Performance
The current stock price of BTAI is 2.05 USD. In the past month the price decreased by -18.97%. In the past year, price decreased by -80.08%.
BTAI Latest News, Press Relases and Analysis
BTAI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 20.59 | 385.18B | ||
| AMGN | AMGEN INC | 13.68 | 160.66B | ||
| GILD | GILEAD SCIENCES INC | 14.63 | 148.64B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.12 | 109.11B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.48 | 69.08B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 350.8 | 59.78B | ||
| ARGX | ARGENX SE - ADR | 61.77 | 50.39B | ||
| INSM | INSMED INC | N/A | 40.08B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.01 | 34.10B | ||
| NTRA | NATERA INC | N/A | 27.30B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.98B | ||
| BIIB | BIOGEN INC | 9.22 | 22.62B |
Related stock screener links
About BTAI
Company Profile
BioXcel Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of artificial intelligence solutions in neuroscience and immuno-oncology. The company is headquartered in New Haven, Connecticut and currently employs 37 full-time employees. The company went IPO on 2018-03-08. Its subsidiary, OnkosXcel Therapeutics LLC, is focused on the development of medicines in immuno-oncology. Its advanced neuroscience candidate, BXCL501, is an investigational, orally dissolving film formulation of dexmedetomidine in development for the treatment of agitation associated with psychiatric and neurological disorders. The company is continuing to develop BXCL501 for the potential acute treatment of agitation associated with bipolar disorder or schizophrenia in the at-home setting and for the potential acute treatment of agitation (non-daily) associated with dementia due to probable Alzheimer’s disease in the at-home setting and in care facilities. Its advanced immuno-oncology candidate, BXCL701, is an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors.
Company Info
BIOXCEL THERAPEUTICS INC
555 Long Wharf Dr
New Haven CONNECTICUT 06511 US
CEO: Vimal Mehta
Employees: 37
Phone: 12036438060
BIOXCEL THERAPEUTICS INC / BTAI FAQ
Can you describe the business of BIOXCEL THERAPEUTICS INC?
BioXcel Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of artificial intelligence solutions in neuroscience and immuno-oncology. The company is headquartered in New Haven, Connecticut and currently employs 37 full-time employees. The company went IPO on 2018-03-08. Its subsidiary, OnkosXcel Therapeutics LLC, is focused on the development of medicines in immuno-oncology. Its advanced neuroscience candidate, BXCL501, is an investigational, orally dissolving film formulation of dexmedetomidine in development for the treatment of agitation associated with psychiatric and neurological disorders. The company is continuing to develop BXCL501 for the potential acute treatment of agitation associated with bipolar disorder or schizophrenia in the at-home setting and for the potential acute treatment of agitation (non-daily) associated with dementia due to probable Alzheimer’s disease in the at-home setting and in care facilities. Its advanced immuno-oncology candidate, BXCL701, is an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors.
What is the stock price of BIOXCEL THERAPEUTICS INC today?
The current stock price of BTAI is 2.05 USD. The price increased by 1.49% in the last trading session.
Does BTAI stock pay dividends?
BTAI does not pay a dividend.
What is the ChartMill rating of BIOXCEL THERAPEUTICS INC stock?
BTAI has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Can you provide the growth outlook for BIOXCEL THERAPEUTICS INC?
The Revenue of BIOXCEL THERAPEUTICS INC (BTAI) is expected to decline by -72.03% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the market capitalization of BTAI stock?
BIOXCEL THERAPEUTICS INC (BTAI) has a market capitalization of 40.28M USD. This makes BTAI a Nano Cap stock.
Can you provide the upcoming earnings date for BIOXCEL THERAPEUTICS INC?
BIOXCEL THERAPEUTICS INC (BTAI) will report earnings on 2025-11-12.
BTAI Technical Analysis
BTAI Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to BTAI. BTAI may be in some trouble as it scores bad on both profitability and health.
BTAI Financial Highlights
Over the last trailing twelve months BTAI reported a non-GAAP Earnings per Share(EPS) of -12.64. The EPS increased by 77.81% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -197.56% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
BTAI Forecast & Estimates
12 analysts have analysed BTAI and the average price target is 18.87 USD. This implies a price increase of 820.49% is expected in the next year compared to the current price of 2.05.
For the next year, analysts expect an EPS growth of 79.16% and a revenue growth -72.03% for BTAI